Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Lymphoma

Free Subscription Articles published in Bone Marrow Transplant Retrieve available abstracts of 48 articles: HTML format

Single Articles

September 2025
1. TORRENT A, Morgades M, Iacoboni G, Reguera JL, et al
   Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy.
   Bone Marrow Transplant. 2025 Sep 30. doi: 10.1038/s41409-025-02722.
   PubMed    
   
   
   August 2025
2. DONG Y, Yang T, Zhao M, Song F, et al
   Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
   Bone Marrow Transplant. 2025 Aug 20. doi: 10.1038/s41409-025-02691.
   PubMed     Abstract available
   
   
   June 2025
3. BEKADJA MA, Niederwieser D, Kharfan-Dabaja MA, El Fakih R, et al
   Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.
   Bone Marrow Transplant. 2025 Jun 30. doi: 10.1038/s41409-025-02664.
   PubMed    
   
   
   
4. DHOLARIA B, Bhaskar ST, Patel VG, Biltibo E, et al
   Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial.
   Bone Marrow Transplant. 2025;60:769-772.
   PubMed     Abstract available
   
   
   May 2025
5. ABDUL WAHID SF, Ismail NA, Md Fauzi MF, Mohd Idris MR, et al
   Clinical outcomes of a new local CD19 CAR-T cell therapy for patients with relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma in Malaysia.
   Bone Marrow Transplant. 2025 May 27. doi: 10.1038/s41409-025-02629.
   PubMed    
   
   
   April 2025
6. ABRAMOVICH A, Adam E, Shapira A, Hutt D, et al
   CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma.
   Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02615.
   PubMed     Abstract available
   
   
   
7. MARTINEZ C, Khvedelidze I, Fekom M, Deau Fischer B, et al
   Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA,
   Bone Marrow Transplant. 2025 Apr 15. doi: 10.1038/s41409-025-02568.
   PubMed     Abstract available
   
   
   
8. DREGER P, Ahmed S, Bazarbachi A, Dietrich S, et al
   How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.
   Bone Marrow Transplant. 2025 Apr 14. doi: 10.1038/s41409-025-02599.
   PubMed     Abstract available
   
   
   
9. SUREDA A, Pavlovsky A, Haidar D, Kristo F, et al
   Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.
   Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02557.
   PubMed     Abstract available
   
   
   
10. ITONAGA H, Fukushima T, Kato K, Muranushi H, et al
    Bone marrow versus peripheral blood stem cells as the graft source for allogeneic transplantation from HLA-matched relative donors in adult T-cell leukemia/lymphoma: A nationwide retrospective study by the ATL working group of the Japanese Society for
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02563.
    PubMed    
    
    
    March 2025
11. CANELO-VILASECA M, Sabbah M, Di Blasi R, Cristinelli C, et al
    Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.
    Bone Marrow Transplant. 2025 Mar 27. doi: 10.1038/s41409-025-02539.
    PubMed     Abstract available
    
    
    
12. KHARFAN-DABAJA MA, Mohty R, Easwar N, Johnston P, et al
    Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.
    Bone Marrow Transplant. 2025 Mar 1. doi: 10.1038/s41409-025-02541.
    PubMed     Abstract available
    
    
    
13. LOSI G, Mussetti A, Pena M, Lopez-Pereira P, et al
    Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas.
    Bone Marrow Transplant. 2025;60:259-269.
    PubMed     Abstract available
    
    
    February 2025
14. KRAMER I, Konig L, Luft T, Hegenbart U, et al
    Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2025 Feb 13. doi: 10.1038/s41409-025-02522.
    PubMed     Abstract available
    
    
    
15. ZHOU J, Wang F, Yang S, Zhang Y, et al
    Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm.
    Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02528.
    PubMed     Abstract available
    
    
    
16. CORONA M, Ip A, Brown S, Luna A, et al
    Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma.
    Bone Marrow Transplant. 2025 Feb 1. doi: 10.1038/s41409-025-02519.
    PubMed     Abstract available
    
    
    December 2024
17. YU F, Niu J, Yang J, Hou J, et al
    Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai.
    Bone Marrow Transplant. 2024 Dec 20. doi: 10.1038/s41409-024-02500.
    PubMed     Abstract available
    
    
    
18. RAMDIAL J, Lin R, Thall PF, Valdez BC, et al
    High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas.
    Bone Marrow Transplant. 2024;59:1754-1762.
    PubMed     Abstract available
    
    
    November 2024
19. MAINGUY A, Soussain C, Touitou V, Bennedjai A, et al
    High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study.
    Bone Marrow Transplant. 2024 Nov 19. doi: 10.1038/s41409-024-02477.
    PubMed     Abstract available
    
    
    
20. RICHARDSON T, Tharmaseelan H, Frenzel L, Godel P, et al
    Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma.
    Bone Marrow Transplant. 2024 Nov 15. doi: 10.1038/s41409-024-02472.
    PubMed    
    
    
    
21. ZHANG X, Xu K, Gale RP, Pan B, et al
    Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2024 Nov 12. doi: 10.1038/s41409-024-02463.
    PubMed     Abstract available
    
    
    October 2024
22. BRAMANTI S, Mannina D, Chiappella A, Casadei B, et al
    Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study.
    Bone Marrow Transplant. 2024 Oct 9. doi: 10.1038/s41409-024-02427.
    PubMed     Abstract available
    
    
    
23. BEKADJA MA, Niederwiser D, Kharfan-Dabaja MA, El Fakih R, et al
    Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2024 Oct 7. doi: 10.1038/s41409-024-02431.
    PubMed     Abstract available
    
    
    September 2024
24. NISHIKUBO M, Shimomura Y, Nakaya Y, Shinohara A, et al
    Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2024 Sep 25. doi: 10.1038/s41409-024-02423.
    PubMed     Abstract available
    
    
    August 2024
25. STEWART C, Owen C, Shafey M, Perry S, et al
    Reappraisal of autologous stem cell transplantation for transformed indolent lymphoma in the bendamustine era.
    Bone Marrow Transplant. 2024 Aug 20. doi: 10.1038/s41409-024-02399.
    PubMed    
    
    
    
26. BEER SA, Mohle R, Tabatabai G, Merle DA, et al
    Clinical relevance of brain MRI changes in primary central nervous system lymphoma after high-dose-chemotherapy and autologous stem cell transplantation.
    Bone Marrow Transplant. 2024 Aug 9. doi: 10.1038/s41409-024-02382.
    PubMed     Abstract available
    
    
    April 2024
27. DONADEL CD, De Santis GC, Goncalves TE, Pires BG, et al
    Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02283.
    PubMed    
    
    
    March 2024
28. MORRIS SL, Thomas BR, Palanicawandar R, Whittaker S, et al
    Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome.
    Bone Marrow Transplant. 2024 Mar 12. doi: 10.1038/s41409-024-02236.
    PubMed     Abstract available
    
    
    
29. GIRARD L, Koh YJ, Koh LP, Chee YL, et al
    Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2024 Mar 5. doi: 10.1038/s41409-024-02254.
    PubMed     Abstract available
    
    
    February 2024
30. NAKAYA Y, Nakamae H, Nishikubo M, Kondo E, et al
    Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma.
    Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02229.
    PubMed     Abstract available
    
    
    
31. HIROSE A, Koh H, Nakamae M, Nakashima Y, et al
    A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02231.
    PubMed    
    
    
    
32. MOSER O, Ngoya M, Galimard JE, Dalissier A, et al
    Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study.
    Bone Marrow Transplant. 2024 Feb 8. doi: 10.1038/s41409-024-02226.
    PubMed     Abstract available
    
    
    
33. AHMADI P, Ghandili S, Jakobs F, Konnopka C, et al
    Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.
    Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02228.
    PubMed    
    
    
    January 2024
34. DE PHILIPPIS C, Zucchinetti C, Mannina D, Krampera M, et al
    Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2024 Jan 25. doi: 10.1038/s41409-024-02205.
    PubMed    
    
    
    
35. CHEN W, Shi J, Luo Y, Yu J, et al
    Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma.
    Bone Marrow Transplant. 2024 Jan 23. doi: 10.1038/s41409-023-02191.
    PubMed    
    
    
    
36. NABERGOJ M, Eikema DJ, Koster L, Platzbecker U, et al
    Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193.
    PubMed     Abstract available
    
    
    
37. OLUWOLE OO, Forcade E, Munoz J, de Guibert S, et al
    Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
    Bone Marrow Transplant. 2024 Jan 4. doi: 10.1038/s41409-023-02169.
    PubMed     Abstract available
    
    
    
38. CABRERO M, Lopez-Corral L, Jarque I, de la Cruz-Vicente F, et al
    Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
    Bone Marrow Transplant. 2024 Jan 2. doi: 10.1038/s41409-023-02171.
    PubMed     Abstract available
    
    
    December 2023
39. ZHANG X, Pang Y, Wei C, Liang D, et al
    Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
    Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
    PubMed    
    
    
    
40. EL WARRAK S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, et al
    Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy.
    Bone Marrow Transplant. 2023 Dec 16. doi: 10.1038/s41409-023-02176.
    PubMed     Abstract available
    
    
    
41. JINDAL N, C M, Mathew LJ, Kumbhalwar K, et al
    Fertility outcomes in patients desiring conception following autologous stem cell transplantation for hodgkin lymphoma using LACE conditioning.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02179.
    PubMed    
    
    
    
42. KATO K, Sugio T, Ikeda T, Yoshitsugu K, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02156.
    PubMed     Abstract available
    
    
    November 2023
43. IQBAL M, Jagadeesh D, Chavez J, Khurana A, et al
    Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Bone Marrow Transplant. 2023 Nov 16. doi: 10.1038/s41409-023-02148.
    PubMed     Abstract available
    
    
    
44. PENA M, Montane C, Paviglianiti A, Hurtado L, et al
    Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas.
    Bone Marrow Transplant. 2023;58:1282-1285.
    PubMed    
    
    
    October 2023
45. GOYAL A, O'Leary D, Foss F
    Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2023 Oct 18. doi: 10.1038/s41409-023-02122.
    PubMed     Abstract available
    
    
    
46. KORESAWA-SHIMIZU R, Suzuki R, Uehara Y, Hiramoto N, et al
    Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry.
    Bone Marrow Transplant. 2023 Oct 7. doi: 10.1038/s41409-023-02118.
    PubMed    
    
    
    September 2023
47. ALEIXO GFP, Wei W, Chen PH, Gandhi NS, et al
    The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2023 Sep 12. doi: 10.1038/s41409-023-02104.
    PubMed     Abstract available
    
    
    
48. BAUR K, Buser A, Jeker LT, Khanna N, et al
    CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas.
    Bone Marrow Transplant. 2023;58:1048-1050.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.